Edwards to launch Sapien XT valve in China in 2013
This article was originally published in Clinica
Edwards Lifesciences intends to launch its Sapien XT transcatheter aortic valve in China in 2013. The first implants of Sapien XT in Chinese patients were performed last month, the Irvine, California-based company said, as special access cases at the Second Military Medical University, under a joint educational and training programme on transcatheter aortic valve implantation between the university and Edwards. The Sapien XT valve was approved for sale in Europe in March 2010 (www.clinica.co.uk, 3 March 2010). It is not yet approved in the US, Japan or China.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.